Literature DB >> 32387111

Understated Cognitive Impairment Assessed with the Clock-Drawing Test in Community-Dwelling Individuals Aged ≥50 Years.

Claire Leissing-Desprez1, Emilie Thomas2, Lauriane Segaux3, Amaury Broussier4, Nadia Oubaya5, Nathalie Marie-Nelly2, Marie Laurent4, Laurent Cleret de Langavant6, Isabelle Fromentin2, Jean-Philippe David4, Sylvie Bastuji-Garin7.   

Abstract

OBJECTIVES: To estimate the prevalence of understated cognitive impairment by administering the Clock-Drawing Test (CDT) to community-dwelling individuals aged ≥50 years and to investigate the associated clinical phenotype.
DESIGN: A cross-sectional analysis of baseline data on community-dwelling individuals assessed at an outpatient clinic in the Paris region of France. SETTING AND PARTICIPANTS: Participants aged ≥50 years (n = 488, median age: 62.1 years) prospectively included in the SUCCessful agEing outpatiEnt's Department survey between 2010 and 2014.
METHODS: A multidimensional geriatric assessment, including cognition [7-point CDT, Mini-Mental State Examination (MMSE), the 5-word screening test (5-WT), and the Frontal Assessment Battery (FAB)], gait speed in dual tasks, mood [the Geriatric Depression Scale (GDS)], balance, physical functions (gait speed and handgrip strength), nutrition, bone density, and comorbidities; major cardiovascular risk factors, and Scheltens and Fazekas scores on brain magnetic resonance imaging. Baseline characteristics were analyzed as a function of the CDT score (<7 vs 7), using age-adjusted logistic models.
RESULTS: The prevalence of impairment in the CDT was 23.6%; higher than the values for the MMSE (12.7%), 5-WT (2.3%), and FAB (16.6%). In age-adjusted analyses, a lower educational level (odds ratio [95% confidence interval] = 0.72 [0.58‒0.89]), diabetes (2.57 [1.14‒5.79]), metabolic syndrome (1.93 [1.05‒3.56]), lower gait speed in the cognitive dual task (1.27 [1.05‒1.53]), a poorer Geriatric Depression Scale score (1.86 [1.04‒3.32]), a poorer MMSE score (2.56 [1.35‒4.88]), a poorer FAB score (1.79 [1.01‒3.16]), impaired episodic memory in the 5-WT (4.11 [1.12‒15.02]), and a higher Scheltens score (P = .001) were significantly associated with CDT impairment. CONCLUSIONS AND IMPLICATIONS: Understated cognitive impairment is common among young seniors and is associated with factors known to be linked to a higher risk of cognitive decline and dementia. These findings suggest that the CDT may be of value for identifying high-risk individuals who may then benefit from targeted multidomain prevention actions (diet, exercise, cognitive training, and vascular risk factor management).
Copyright © 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clock-Drawing Test; Understated cognitive impairment; elderly; middle-aged; screening

Mesh:

Year:  2020        PMID: 32387111     DOI: 10.1016/j.jamda.2020.03.016

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  3 in total

1.  The montreal cognitive assessment and mini-mental state examination visuoexecutive subtests in acute ischemic stroke patients and their correlations with demographic and clinical factors.

Authors:  Wei Wang; Fang-Ming Dong; Kai Shao; Shang-Zun Guo; Zhong-Min Zhao; Yi-Ming Yang; Ya-Xue Song; Jian-Hua Wang
Journal:  Acta Neurol Belg       Date:  2020-11-21       Impact factor: 2.396

2.  Clock-Drawing Test as a Screening Tool for Cognitive Impairment Associated With Fecal Immunochemical Test Collection Errors.

Authors:  Jeanette M Daly; Yinghui Xu; Seth D Crockett; Megan E Schmidt; Peter Kim; Barcey T Levy
Journal:  Ann Fam Med       Date:  2022 Sep-Oct       Impact factor: 5.707

3.  Cognitive dysfunction correlates with physical impairment in frail patients with acute myocardial infarction.

Authors:  Pasquale Mone; Jessica Gambardella; Antonella Pansini; Giuseppe Martinelli; Fabio Minicucci; Ciro Mauro; Gaetano Santulli
Journal:  Aging Clin Exp Res       Date:  2021-06-08       Impact factor: 3.636

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.